Decheng Capital LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 2010850) · Explore on the interactive board
Decheng Capital LLC disclosed 14 US equity positions worth $731.7m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is CGON at 61.9% of the reported book, followed by NUVB, AARD. The top ten holdings are 98.1% of the book, and the portfolio behaves like about 2 equal-weight positions. Versus the prior filing it opened 1 new position, added to 0, reduced 3 and exited 1. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Decheng Capital LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 1 new, 0 added, 3 reduced, 1 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | Healthcare | 61.9% | $452.7m | 6,371,669 | 0% | held |
| 2 | NUVB Nuvation Bio Inc. | Healthcare | 20.1% | $147.4m | 25,954,439 | 0% | held |
| 3 | AARD AARDVARK THERAPEUTICS INC | 3.1% | $22.6m | 3,917,299 | 0% | held | |
| 4 | ACRS Aclaris Therapeutics, Inc. | Healthcare | 2.9% | $21.4m | 4,041,736 | 0% | held |
| 5 | UPB Upstream Bio Inc. | 2.6% | $18.9m | 2,724,868 | 0% | held | |
| 6 | RCUS Arcus Biosciences, Inc | Healthcare | 2.0% | $14.3m | 464,779 | -3% | reduced |
| 7 | EQ Equillium Inc. | 1.9% | $14.2m | 4,447,308 | 0% | held | |
| 8 | RVMD REVOLUTION MEDICINES INC(NSM) | Healthcare | 1.3% | $9.9m | 52,667 | -44% | reduced |
| 9 | LYEL Lyell Immunopharma, Inc. | 1.3% | $9.7m | 692,050 | 0% | held | |
| 10 | BYSI BeyondSpring Inc. | 0.9% | $6.7m | 3,800,702 | 0% | held | |
| 11 | ZNTL Zentalis Pharmaceuticals Inc. | Healthcare | 0.9% | $6.4m | 1,323,327 | 0% | held |
| 12 | NEWAMSTERDAM PHARMA CO NV | 0.8% | $6.0m | 176,887 | -46% | reduced | |
| 13 | PYXS Pyxis Oncology, Inc (formerly Apexigen) | 0.1% | $983.7k | 326,810 | 0% | held | |
| 14 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.1% | $625.2k | 20,000 | – | new |
What did Decheng Capital LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| KRYS KRYSTAL BIOTECH INC | 100.0% | $1.9m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 89.2% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Decheng Capital LLC's portfolio?
Across every quarter Decheng Capital LLC has filed, its median largest position is 63.5% of the book and its median top-ten weight is 98.2%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 1.0 completed holding spells, the median lasted 1.0 quarters; 14.0 positions are still open and their final length is unknown.